Three minutes after administration of NIMBEX:

  • 4 NiMBex patients showed a change greater than +/-20% in heart rate (HR) or mean arterial pressure (MAP) from induction in pooled data1
  • No treatment was required for MAP of HR changes1
  • NiMBex will not counteract the bradycardia produced by many anesthetic agents or by vagal stimulation2
  • NiMBex has no dose-related effects on MAP or HR following doses ranging from 2-8x ED95 administered over 5 to 10 seconds in healthy adult patients or in patients with serious cardiovascular disease2

© 2022 AbbVie. All rights reserved.
ULTANE® and its design are registered trademarks of AbbVie Inc.
NIMBEX® and its design are trademarks of GlaxoSmithKline LLC, used under license by AbbVie Inc.
US-NIMB-220002 November 2022

AbbVie logo